Bristol-Myers Squibb raised its full-year 2025 guidance to a revenue range of $45.8 billion to $46.8 billion and non-GAAP diluted earnings per share of $6.70 to $7.00.

According to "Q1 2025 Results": Bristol-Myers Squibb raised its full-year 2025 guidance to a revenue range of $45.8 billion to $46.8 billion and non-GAAP diluted earnings per share of $6.70 to $7.00.

The company’s growth portfolio achieved a 16% year-over-year increase in net sales, driven by strong demand for Opdivo, Breyanzi, and Camzyos.

According to "Q1 2025 Results": The company’s growth portfolio achieved a 16% year-over-year increase in net sales, driven by strong demand for Opdivo, Breyanzi, and Camzyos.

Total global net sales for Q1 2025 were $11.2 billion, representing a 6% decline compared to the same period in 2024 due to generic competition for legacy products like Revlimid, Sprycel, and Pomalyst.

According to "Q1 2025 Results": Total global net sales for Q1 2025 were $11.2 billion, representing a 6% decline compared to the same period in 2024 due to generic competition for legacy products like Revlimid, Sprycel, and Pomalyst.

The company has paid down approximately $6 billion of its $10 billion debt reduction target while continuing to prioritize shareholder dividends and share repurchases.

According to "Q1 2025 Results": The company has paid down approximately $6 billion of its $10 billion debt reduction target while continuing to prioritize shareholder dividends and share repurchases.

Operational progress includes the successful U.S. launch of Opdivo Qvantig and a pipeline strategy focused on multiple pivotal data readouts for new molecular entities through 2027.

According to "Q1 2025 Results": Operational progress includes the successful U.S. launch of Opdivo Qvantig and a pipeline strategy focused on multiple pivotal data readouts for new molecular entities through 2027.

Back to report

Key Insights

Q1 2025 Results

Bristol-Myers Squibb~13 min full read

01
Bristol-Myers Squibb raised its full-year 2025 guidance to a revenue range of $45.8 billion to $46.8 billion and non-GAAP diluted earnings per share of $6.70 to $7.00.
See it on page 4
02
The company’s growth portfolio achieved a 16% year-over-year increase in net sales, driven by strong demand for Opdivo, Breyanzi, and Camzyos.
See it on page 7
03
Total global net sales for Q1 2025 were $11.2 billion, representing a 6% decline compared to the same period in 2024 due to generic competition for legacy products like Revlimid, Sprycel, and Pomalyst.
See it on page 4
04
The company has paid down approximately $6 billion of its $10 billion debt reduction target while continuing to prioritize shareholder dividends and share repurchases.
See it on page 14
05
Operational progress includes the successful U.S. launch of Opdivo Qvantig and a pipeline strategy focused on multiple pivotal data readouts for new molecular entities through 2027.
See it on page 8

That's the gist.

Dive into the full report for the data, charts, and sources behind these takeaways.

Read the full report